» Articles » PMID: 37091071

An R Shiny App for a Chronic Lower Back Pain Study, Personalized N-of-1 Trial

Overview
Publisher MIT Press
Date 2023 Apr 24
PMID 37091071
Authors
Affiliations
Soon will be listed here.
Abstract

The call for personalized medicine highlights the need for personalized (N-of-1) trials to find what treatment works best for individual patients. Conventional (between-subject) randomized controlled trials (RCT) yield effects for the 'average patient,' but a personalized trial administers all treatments within-subject, so benefits or harms to the individual patient can be identified. The design and analysis of personalized trials involve different strategies from the conventional RCT. These include how to adjust for any carryover effects from one intervention to another, how to handle missing data, and how to provide patients with insight into their data. In addition, a comprehensible report about trial results should be created for each patient and their clinician to facilitate their decision-making. This article describes strategies to address these design and analytic issues, and introduces an R shiny app to facilitate their solution, to explain the use of each of the design and statistical strategies. To illustrate, we also provide a concrete example of a personalized trial series designed to increase activity (i.e., walking steps) in patients with chronic lower back pain (CLBP).

Citing Articles

Personalized Feedback for Personalized Trials: Construction of Summary Reports for Participants in a Series of Personalized Trials for Chronic Lower Back Pain.

DAngelo S, Ahn H, Miller D, Monane R, Butler M Harv Data Sci Rev. 2023; 4(SI3).

PMID: 38009134 PMC: 10673635. DOI: 10.1162/99608f92.d5b57784.


Introducing Data Sciences to N-of-1 Designs, Statistics, Use-Cases, the Future, and the Moniker 'N-of-1' Trial.

Davidson K, Cheung Y, Friel C, Suls J Harv Data Sci Rev. 2023; 4(SI3).

PMID: 38009132 PMC: 10673636. DOI: 10.1162/99608f92.116c43fe.


N-of-1 trials: The epitome of personalized medicine?.

Samuel J, Wootton S, Tyson J J Clin Transl Sci. 2023; 7(1):e161.

PMID: 37528940 PMC: 10388431. DOI: 10.1017/cts.2023.583.

References
1.
Willan A, Pater J . Carryover and the two-period crossover clinical trial. Biometrics. 1986; 42(3):593-9. View

2.
Freeman P . The performance of the two-stage analysis of two-treatment, two-period crossover trials. Stat Med. 1989; 8(12):1421-32. DOI: 10.1002/sim.4780081202. View

3.
Guyatt G, Sackett D, Taylor D, Chong J, Roberts R, Pugsley S . Determining optimal therapy--randomized trials in individual patients. N Engl J Med. 1986; 314(14):889-92. DOI: 10.1056/NEJM198604033141406. View

4.
Dowell D, Haegerich T, Chou R . CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016; 315(15):1624-45. PMC: 6390846. DOI: 10.1001/jama.2016.1464. View

5.
Araujo A, Julious S, Senn S . Understanding Variation in Sets of N-of-1 Trials. PLoS One. 2016; 11(12):e0167167. PMC: 5131970. DOI: 10.1371/journal.pone.0167167. View